Optos has reported 14% growth for the year ended March 2022, resulting in record group revenues of $254m.
The Fife-headquartered advanced retinal imaging company's growth coincides with its 30th anniversary.
Optos now has four core imaging platforms - the Daytona, California, Monaco and Silverstone - with more than 22,000 devices across the world using the technology.
Its most recent addition is the first ultra-widefield (UWF) artificial intelligence (AI) system, which facilitates early detection and management of diabetic retinopathy (DR), a leading cause of blindness among adults worldwide.
This spring, Optos AI was unveiled and has already achieved CE marking in the UK and European Union. Using optomap UWF images, the system provides automated evaluation of more-than-mild diabetic retinopathy and diabetic macular oedema.
Based in Dunfermline, the business was founded in 1992 by Douglas Anderson after his five-year old son lost his sight in one eye due to a retinal detachment, despite regular eye examinations.
Determined to enable eye problems to be detected as early as possible, he set out with the goal to make a patient-friendly device to capture an ultra-widefield image of the retina. Through this, Optos developed a device capable of high resolution digital images, called optomap.
The business has continued to invest into research and development, with $18.6m put back in during the last financial year, up more than 40% on the previous year.
Globally, more than 500 people are employed by Optos in a variety of roles including development, manufacturing, clinical research and sales.
Rob Kennedy, chief executive of Optos, said: “We are proud of what Optos has achieved over the past three decades - we have remained true to Douglas’s core purpose of improving patient outcomes by providing the best imaging technology.
“We have delivered significant growth, continued to develop our technology, and ultimately enabled our customers to help save the sight of their patients.”
The company was acquired by Nikon in 2015.
Don't miss the latest headlines with our twice-daily newsletter - sign up here for free .
